vs
Apple Hospitality REIT, Inc.（APLE）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apple Hospitality REIT, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$326.4M vs $199.9M），Apple Hospitality REIT, Inc.净利率更高（9.1% vs -29.5%，领先38.6%），Apple Hospitality REIT, Inc.同比增速更快（-2.0% vs -5.9%），Apple Hospitality REIT, Inc.自由现金流更多（$282.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -0.5%）
莱曼 hospitality properties是一家深耕酒店、度假村、娱乐及媒体领域的企业，得名于旗下核心资产——位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾作为爱德华·盖洛德旗下俄克拉荷马出版公司子公司的时期，1983年收购WSM公司后，拿下大奥普里等知名IP，奠定了如今的业务发展基础。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
APLE vs APLS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $326.4M | $199.9M |
| 净利润 | $29.6M | $-59.0M |
| 毛利率 | 37.2% | — |
| 营业利润率 | 15.2% | -25.6% |
| 净利率 | 9.1% | -29.5% |
| 营收同比 | -2.0% | -5.9% |
| 净利润同比 | -0.7% | -62.2% |
| 每股收益（稀释后） | $0.13 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $326.4M | $199.9M | ||
| Q3 25 | $373.9M | $458.6M | ||
| Q2 25 | $384.4M | $178.5M | ||
| Q1 25 | $327.7M | $166.8M | ||
| Q4 24 | $333.0M | $212.5M | ||
| Q3 24 | $378.8M | $196.8M | ||
| Q2 24 | $390.1M | $199.7M | ||
| Q1 24 | $329.5M | $172.3M |
| Q4 25 | $29.6M | $-59.0M | ||
| Q3 25 | $50.9M | $215.7M | ||
| Q2 25 | $63.6M | $-42.2M | ||
| Q1 25 | $31.2M | $-92.2M | ||
| Q4 24 | $29.8M | $-36.4M | ||
| Q3 24 | $56.3M | $-57.4M | ||
| Q2 24 | $73.9M | $-37.7M | ||
| Q1 24 | $54.0M | $-66.4M |
| Q4 25 | 37.2% | — | ||
| Q3 25 | 40.6% | — | ||
| Q2 25 | 42.6% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 41.9% | — | ||
| Q2 24 | 44.6% | — | ||
| Q1 24 | 40.1% | — |
| Q4 25 | 15.2% | -25.6% | ||
| Q3 25 | 19.4% | 48.7% | ||
| Q2 25 | 22.1% | -18.6% | ||
| Q1 25 | 15.5% | -50.0% | ||
| Q4 24 | 15.0% | -12.3% | ||
| Q3 24 | 20.5% | -24.0% | ||
| Q2 24 | 24.0% | -14.7% | ||
| Q1 24 | 21.7% | -36.0% |
| Q4 25 | 9.1% | -29.5% | ||
| Q3 25 | 13.6% | 47.0% | ||
| Q2 25 | 16.6% | -23.6% | ||
| Q1 25 | 9.5% | -55.3% | ||
| Q4 24 | 9.0% | -17.1% | ||
| Q3 24 | 14.9% | -29.2% | ||
| Q2 24 | 19.0% | -18.9% | ||
| Q1 24 | 16.4% | -38.5% |
| Q4 25 | $0.13 | $-0.40 | ||
| Q3 25 | $0.21 | $1.67 | ||
| Q2 25 | $0.27 | $-0.33 | ||
| Q1 25 | $0.13 | $-0.74 | ||
| Q4 24 | $0.13 | $-0.30 | ||
| Q3 24 | $0.23 | $-0.46 | ||
| Q2 24 | $0.31 | $-0.30 | ||
| Q1 24 | $0.22 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $466.2M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $3.1B | $370.1M |
| 总资产 | $4.9B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $466.2M | ||
| Q3 25 | $50.3M | $479.2M | ||
| Q2 25 | $7.9M | $370.0M | ||
| Q1 25 | $14.9M | $358.4M | ||
| Q4 24 | $10.3M | $411.3M | ||
| Q3 24 | $6.1M | $396.9M | ||
| Q2 24 | $7.2M | $360.1M | ||
| Q1 24 | $4.9M | $325.9M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | $93.1M |
| Q4 25 | $3.1B | $370.1M | ||
| Q3 25 | $3.2B | $401.2M | ||
| Q2 25 | $3.2B | $156.3M | ||
| Q1 25 | $3.2B | $164.2M | ||
| Q4 24 | $3.3B | $228.5M | ||
| Q3 24 | $3.3B | $237.1M | ||
| Q2 24 | $3.3B | $264.3M | ||
| Q1 24 | $3.3B | $266.7M |
| Q4 25 | $4.9B | $1.1B | ||
| Q3 25 | $4.9B | $1.1B | ||
| Q2 25 | $4.9B | $821.4M | ||
| Q1 25 | $4.9B | $807.3M | ||
| Q4 24 | $5.0B | $885.1M | ||
| Q3 24 | $5.0B | $901.9M | ||
| Q2 24 | $5.1B | $904.5M | ||
| Q1 24 | $5.0B | $831.9M |
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.46× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.45× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $370.2M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $282.0M | $-14.3M |
| 自由现金流率自由现金流/营收 | 86.4% | -7.1% |
| 资本支出强度资本支出/营收 | 27.0% | 0.1% |
| 现金转化率经营现金流/净利润 | 12.50× | — |
| 过去12个月自由现金流最近4个季度 | $516.8M | $45.0M |
8季度趋势，按日历期对齐
| Q4 25 | $370.2M | $-14.2M | ||
| Q3 25 | $126.4M | $108.5M | ||
| Q2 25 | $108.8M | $4.4M | ||
| Q1 25 | $49.1M | $-53.4M | ||
| Q4 24 | $405.4M | $19.4M | ||
| Q3 24 | $128.2M | $34.1M | ||
| Q2 24 | $127.3M | $-8.3M | ||
| Q1 24 | $54.7M | $-133.0M |
| Q4 25 | $282.0M | $-14.3M | ||
| Q3 25 | $109.0M | $108.3M | ||
| Q2 25 | $96.2M | $4.4M | ||
| Q1 25 | $29.5M | $-53.4M | ||
| Q4 24 | $327.1M | $19.3M | ||
| Q3 24 | $113.1M | — | ||
| Q2 24 | $115.0M | $-8.4M | ||
| Q1 24 | $34.4M | $-133.3M |
| Q4 25 | 86.4% | -7.1% | ||
| Q3 25 | 29.2% | 23.6% | ||
| Q2 25 | 25.0% | 2.5% | ||
| Q1 25 | 9.0% | -32.0% | ||
| Q4 24 | 98.2% | 9.1% | ||
| Q3 24 | 29.9% | — | ||
| Q2 24 | 29.5% | -4.2% | ||
| Q1 24 | 10.4% | -77.3% |
| Q4 25 | 27.0% | 0.1% | ||
| Q3 25 | 4.7% | 0.0% | ||
| Q2 25 | 3.3% | 0.0% | ||
| Q1 25 | 6.0% | 0.0% | ||
| Q4 24 | 23.5% | 0.0% | ||
| Q3 24 | 4.0% | 0.0% | ||
| Q2 24 | 3.2% | 0.0% | ||
| Q1 24 | 6.2% | 0.2% |
| Q4 25 | 12.50× | — | ||
| Q3 25 | 2.49× | 0.50× | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 1.57× | — | ||
| Q4 24 | 13.59× | — | ||
| Q3 24 | 2.28× | — | ||
| Q2 24 | 1.72× | — | ||
| Q1 24 | 1.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLE
| Occupancy | $293.0M | 90% |
| Hotel Other | $17.2M | 5% |
| Food And Beverage | $16.3M | 5% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
